TC-5214 (S-(+)-mecamylamine): A neuronal nicotinic receptor modulator with antidepressant activity

CNS Neuroscience and Therapeutics

Volumn 14, Issue 4, 2008, Pages 266-277

  Lippiello, Patrick M ^a   Beaver, Jessica S ^a   Gatto, Gregory J ^a   James, John W ^a   Jordan, Kristen G ^a   Traina, Vincent M ^a   Xie, Jianxun ^a   Bencherif, Merouane ^a  

^a TARGACEPT INC   (United States)

Author keywords

Acetylcholine; Depression; Mecamylamine; Nicotinic

Indexed keywords

CLOBAZAM; CYTISINE; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; MECAMYLAMINE; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; PARGYLINE; PARTIAL AGONIST; RECEPTOR SUBTYPE; TC 2216; TC 5213; TC 5214; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANXIETY DISORDER; AREA UNDER THE CURVE; BEHAVIORAL DESPAIR TEST; CHRONIC TOXICITY; DEPRESSION; DISTRIBUTION VOLUME; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; FORCED SWIMMING TEST; GENERALIZED ANXIETY DISORDER; HUMAN; MUTAGENICITY; NONHUMAN; PHOBIA; PSYCHOLOGIC TEST; REVIEW; SOCIAL INTERACTION; TRANQUILIZING ACTIVITY;

ANIMALS; ANTIDEPRESSIVE AGENTS; CHROMOSOME ABERRATIONS; DOGS; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; GASTROINTESTINAL MOTILITY; HUMANS; MALE; MECAMYLAMINE; MICE; MICRONUCLEUS TESTS; NICOTINIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; SOCIAL BEHAVIOR; STEREOISOMERISM;

EID: 55849083148     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2008.00054.x     Document Type: Review

References (44)

1. Janowsky D, El-Yousef MK, Davis JM. Acetylcholine and depression. Psychosomatic Med 1974 36 : 248 257.
2. Janowsky DS, Risch SC. Cholinomimetic and anticholinergic drugs used to investigate and acetylcholine hypothesis of affective disorders and stress. Drug Development Res 1984 4 : 125 142.
3. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR. Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 2002 7 : 525 535.
4. Picciotto MR, Brunzell DH, Caldarone BJ. Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport 2002 13 : 1097 1106.
5. Fryer JD, Lukas RJ. Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function. J Neurochem 1999 72 : 1117 1124.
6. Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 1999 288 : 88 92.
7. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000 295 : 321 327.
8. Newman MB, Manresa JJ, Sanberg PR, Shytle RD. Anxiolytic effects of mecamylamine in two animal models of anxiety. Exp Clin Psychopharmacology 2002 10 : 18 25.
9. Salín-Pascual RJ, Drucker-Colín R. A novel effect of nicotine on mood and sleep in major depression. Neuroreport 1998 9 : 57 60.
10. Caldarone BJ, Harrist A, Cleary MA, Beech RD, King SL, Picciotto MR. High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation. Biol Psychiatry 2004 5 : 657 664.
11. Mineur YS, Somenzi O, Picciotto MR. Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57 BL/6 J mice. Neuropharmacology 2007 52 : 256 1262.
12. Rabenstein RM, Calderone BJ, Piccciotto MR. The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2 or alpha7 nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology 2006 189 : 395 401.
13. Labarca C, Schwarz J, Deshpande P, Schwarz S, Nowak MW, Fonck C, Nashmi R, Kofuji P, Dang H, Shi W et al. Point mutant mice with hypersensitive alpha 4 nicotinic receptors show dopaminergic deficits and increased anxiety. Proc Natl Acad Sci USA 2001 98 : 2786 2791.
14. Buisson B, Bertrand D. Chronic exposure to nicotine upregulates the human alpha4beta2 nicotinic acetylcholine receptor function. J Neurosci 2001 21 : 1819 1829.
15. Nelson ME, Kuryatov A, Choi CH, Zhou Y, Lindstrom J. Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors. Mol Pharmacol 2003 63 : 332 341.
16. Moroni M, Zwart R, Sher E, Cassels BK, Bermudez I. Alpha4beta2 nicotinic receptors with high and low acetylcholine sensitivity: Pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine. Mol Pharmacol 2006 70 : 755 768.
17. Briggs CA, Gubbins EJ, Putman CB, Thimmapaya R, Meyer MD, Surowy CS. High- and low-sensitivity subforms of alpha4beta2 and alpha3beta2 nAChRs. J Mol Neurosci 2006 30 : 11 12.
18. Freis ED, Wilson IM. Mecamylamine, a new, orally effective, hypotensive agent;experimental and clinical evaluation. AMA Arch Intern Med 1956 97 : 551 561.
19. Newman MB, Manresa JJ, Sanberg PR, Shytle RD. Nicotine induced seizures blocked by mecamylamine and its stereoisomers. Life Sci 2001 69 : 2583 2591.
20. Rang HP. Drugs and ionic channels: Mechanisms and implications. Postgrad Med J 1981 57 (Suppl. 1 89 97.
21. 3H]-mecamylamine binding to rat brain membranes. Studies with mecamylamine and nicotine analogues. Biochem Pharmacol 1990 40 : 2105 2110.
22. Silver AA, Shytle RD, Sanberg PR. Mecamylamine in Tourette's syndrome: A two-year retrospective case study. J Child Adult Psychopharmacol 2000 10 : 59 68.
23. Shytle RD, Silver AA, Sanberg PR. Comorbid bipolar disorder in Tourette's syndrome responds to the nicotinic receptor antagonist mecamylamine (Inversine). Biol Psychiatry 2000 48 : 1028 1031.
24. Silver AA, Shytle RD, Sheehan KH, Sheehan DV, Ramos A, Sanberg PR. Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's Disorder. J Am Acad Child Adolesc Psychiatry 2001 40 : 1103 1110.
25. Porsolt RD, LePichon M, Jalfre M. Depression: A new animal model sensitive to antidepressant treatment. Nature 1977 266 : 730 732.
26. File SE, Lippa AS, Beer B, Lippa MT. Animal tests of anxiety. Curr Protoc Pharmacol 2004 38 : 1 21.
27. Picciotto MR. Nicotine as a modulator of behavior: Beyond the inverted U. Trends Pharmacol Sci 2003 24 : 9493 9499.
28. Cheeta S, Irvine E, File SE. Social isolation modifies nicotine's effects in animal tests of anxiety. Br J Pharmacol 2001 132 : 1389 1395.
29. Tucci S, Cheeta S, Genn RF, Seth P, File SE. Anxiety conditioned to nicotine in the elevated plus-maze is time dependent. Behav Pharmacol 2002 13 : 615 620.
30. Young JM, Shytle RD, Sanberg PR, George TP. Mecamylamine: New therapeutic uses and toxicity/risk profile. Clin Ther 2001 23 : 532 565.
31. Nemeroff CB. The neurobiology of depression. Sci American 1998 278 : 42 49.
32. Azam L, Winzer-Serhan UH, Chen Y, Leslie FM. Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs within midbrain dopamine neurons. J Comp Neurol 2002 444 : 260 274.
33. Rossi S, Singer S, Shearman E, Sershen H, Lajtha A. The effects of cholinergic and dopaminergic antagonists on nicotine-induced cerebral neurotransmitter changes. Neurochem Res 2005 30 : 541 558.
34. Hildebrand BE, Nomikos GG, Hertel P, Schilström B, Svensson TH. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res 1998 779 : 214 225.
35. Schilström B, Rawal N, Mameli-Engvall M, Nomikos GG, Svensson TH. Dual effects of nicotine on dopamine neurons mediated by different nicotinic receptor subtypes. Int J Neuropsychopharmacol 2003 6 : 1 11.
36. Vincler MA, Eisenach JC. Immunocytochemical localization of the alpha3, alpha4, alpha5, alpha7, beta2, beta3 and beta4 nicotinic acetylcholine receptor subunits in the locus coeruleus of the rat. Brain Res 2003 974 : 25 36.
37. O'Leary KT, Leslie FM. Enhanced nicotinic acetylcholine receptor-mediated [3 H]norepinephrine release from neonatal rat hypothalamus. Neuropharmacology 2006 50 : 81 88.
38. Matta SG, Fu Y, Valentine JD, Sharp BM. Response of the hypothalamo-pituitary-adrenal axis to nicotine. Psychoneuroendocrinology 1998 23 : 103 113.
39. Pick M, Flores-Flores C, Soreq H. From brain to blood: Alternative splicing evidence for the cholinergic basis of Mammalian stress responses. Ann N Y Acad Sci 2004 1018 : 85 98.
40. Rubin RT, O'Toole SM, Rhodes ME, Sekula LK, Czambel RK. Hypothalamo-pituitary-adrenal cortical responses to low-dose physostigmine and arginine vasopressin administration: Sex differences between major depressives and matched control subjects. Psychiatry Res 1999 89 : 1 20.
41. Takita M, Taniguchi T, Zhu J, Piao HL, Tsai TY, Muramatsu I. Effects of chronic treatment with (+)-nicotine on the stress-induced hypertension and downregulation of central nicotinic receptors in rats: Comparative study with (-)-nicotine. Gen Pharmacol 1999 33 : 29 33.
42. Raber J, Koob GF, Bloom FE. Interleukin-2 (IL-2) induces corticotrophin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling; comparison with the hypothalamic response. J Pharmacol Exp Ther 1995 272 : 815 824.
43. Newman MB, Nazian SJ, Sanberg PR, Diamond DM, Shytle RD. Corticosterone-attenuating and anxiolytic properties of mecamylamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry 2001 25 : 609 620.
44. Bugajski J, Gadek-Michalska A, Bugajski AJ. Involvement of prostaglandins in the nicotine-induced pituitary-adrenocortical response during social stress. J Physiol Pharmacol 2002 53 : 847 857.